tldrdaily.news logo
Tag

Businesshealth

All articles tagged with #businesshealth

Zealand Pharma's Weight-Loss Drug Petrelintide Shows Promising Trial Results, Shares Surge 17%
businesshealth1 year ago

Zealand Pharma's Weight-Loss Drug Petrelintide Shows Promising Trial Results, Shares Surge 17%

Zealand Pharma's shares surged 18% after positive early-stage trial results for its weight loss drug petrelintide, which showed an average body weight reduction of 8.6% compared to 1.7% with a placebo. The drug was deemed safe and well-tolerated, positioning it as a potential alternative to GLP-1 receptor agonist-based therapies like Novo Nordisk's Ozempic. The company plans to proceed with a phase 2 clinical trial.

via CNBC|
#businesshealth#clinical-trial#petrelintide
"Seattle's Bartell's Closure: A Blow to Local Consumers"
businesshealth1 year ago

"Seattle's Bartell's Closure: A Blow to Local Consumers"

The American pharmacy industry is facing a severe crisis, exemplified by the closure of many Bartell Drugs locations in Seattle following Rite Aid's bankruptcy. Factors such as competition from online retailers, reduced reimbursements from pharmacy benefit managers (PBMs), and the opioid crisis have led to widespread pharmacy shutdowns. This has created "pharmacy deserts," particularly affecting underserved communities. The situation is dire for both large chains and independent pharmacies, with many struggling to stay afloat amid financial pressures and changing market dynamics.

via Fortune|
#businesshealth#pbm-impact#pharmacy-closures
Pfizer's Lung Cancer Drug Projected to Surpass $1 Billion in Sales
businesshealth1 year ago

Pfizer's Lung Cancer Drug Projected to Surpass $1 Billion in Sales

Pfizer anticipates its lung cancer drug Lorbrena will surpass $1 billion in annual sales by 2030, driven by strong five-year clinical trial data showing significant disease progression-free survival rates in patients with ALK-positive advanced lung cancer. The drug, which outperforms Pfizer's earlier treatment Xalkori, has shown particularly promising results in patients with brain metastases and is expected to see substantial market growth, especially in China.

via Fox Business|
#alk-mutation#businesshealth#lorbrena
Summit Therapeutics Stock Skyrockets After Cancer Drug Outperforms Keytruda
businesshealth1 year ago

Summit Therapeutics Stock Skyrockets After Cancer Drug Outperforms Keytruda

Summit Therapeutics Inc. shares soared 272% after a late-stage trial showed their cancer drug ivonescimab significantly outperformed Merck's Keytruda in treating non-small cell lung cancer, leading to a decline in Merck's shares. The trial, conducted in China, demonstrated a meaningful improvement in progression-free survival, with analysts optimistic about the drug's potential in other populations and across multiple solid tumors.

via Yahoo Finance|
#businesshealth#cancer-drug#ivonescimab
Eli Lilly Invests $5.3B to Boost Zepbound and Mounjaro Production
businesshealth1 year ago

Eli Lilly Invests $5.3B to Boost Zepbound and Mounjaro Production

Eli Lilly is investing over $5 billion to expand manufacturing in Indiana for its popular weight loss and diabetes drugs, Zepbound and Mounjaro, due to high demand. This investment, the largest in the company's history, aims to produce the main ingredient, Tirzepatide, and is expected to create numerous high-wage jobs. The new site will start production in 2026, with full output by 2028, and is part of a broader initiative to boost local infrastructure and workforce development.

via The US Sun|
#businesshealth#eli-lilly#indiana
Vaccine Stocks Surge on Predicted COVID-19 Case Rise
businesshealth1 year ago

Vaccine Stocks Surge on Predicted COVID-19 Case Rise

Shares of COVID-19 vaccine makers like Moderna, Pfizer, BioNTech, and Novavax are rebounding as they pivot to new growth opportunities post-pandemic. Pfizer has acquired Seagen to focus on cancer drugs, Moderna awaits FDA approval for an RSV vaccine, BioNTech is diversifying its pipeline, and Novavax has a new licensing deal with Sanofi. These companies are outperforming the broader biotech sector despite past revenue declines.

via Seeking Alpha|
#biotech#businesshealth#covid-19
Chick-fil-A Reverses Antibiotic-Free Chicken Pledge, Citing Supply Shortages
businesshealth1 year ago

Chick-fil-A Reverses Antibiotic-Free Chicken Pledge, Citing Supply Shortages

Chick-Fil-A is abandoning its "no antibiotics ever" pledge and shifting to a policy that limits the use of antibiotics important to human medicine in its chicken supply chain, citing concerns about acquiring enough antibiotic-free chicken. This move follows similar actions by Tyson Foods, which reintroduced some antibiotics to its chicken production, citing scientific research and industry learnings. Livestock producers have historically used antibiotics to promote growth in animals, but concerns about antibiotic resistance and human health have led to increased restrictions on their use.

via The Associated Press|
#antibiotic-resistance#antibiotics#businesshealth
"Eli Lilly Expands Access and Takes Stand on Drug Use Amidst Industry Shifts"
businesshealth2 years ago

"Eli Lilly Expands Access and Takes Stand on Drug Use Amidst Industry Shifts"

Eli Lilly has launched LillyDirect, a telehealth platform designed to streamline access to its weight loss drug, Zepbound, and other medications. The platform connects patients with independent telehealth providers and prescription delivery services. While the initiative aims to ensure patients receive genuine medications and facilitate the use of coupons, healthcare professionals express concerns over the potential for biased treatment and the commodification of medicine. Critics argue that direct-to-consumer medication services may prioritize company profits over patient care, and that in-person exams are crucial for comprehensive obesity treatment. Despite these concerns, the trend towards telehealth platforms for prescribing weight loss medications is growing, with companies like Ro and WeightWatchers also entering the space.

via The New York Times|
#businesshealth#eli-lilly#mounjaro
"Novartis and Voyager Therapeutics Forge $1.2 Billion Neurologic Gene Therapy Alliance"
businesshealth2 years ago

"Novartis and Voyager Therapeutics Forge $1.2 Billion Neurologic Gene Therapy Alliance"

Novartis has expanded its gene therapy collaboration with Voyager Therapeutics, investing $100 million upfront to acquire capsids targeting Huntington’s disease and spinal muscular atrophy. The announcement, which comes ahead of the JP Morgan Healthcare Conference, has already positively impacted Voyager's stock, with shares increasing by 32%. Additionally, Novartis will purchase $20 million in Voyager shares, further cementing the partnership between the two companies in the field of neurologic gene therapies.

via Endpoints News|
##businesshealth#genetherapy
"Tome Biosciences Expands Genome Editing Reach with Replace Therapeutics Acquisition"
businesshealth2 years ago

"Tome Biosciences Expands Genome Editing Reach with Replace Therapeutics Acquisition"

Tome Biosciences, a gene editing company, has acquired Replace Therapeutics for $65 million upfront, with potential total payments reaching $185 million. This acquisition, shortly after Tome's launch with substantial funding, aims to enhance its DNA editing capabilities by integrating Replace's technology for making precise, smaller-scale changes to the genome. This complements Tome's existing CRISPR-based technology for inserting larger DNA sequences.

via Endpoints News|
##acquisition#businesshealth